CEO’s Unplanned Share Sale Amid Surge Raises Concerns Over UniQure’s Short‑Term Outlook
CEO insider sell‑off sparks debate on UniQure’s gene‑therapy outlook, raising questions about management confidence amid strong market gains.
2 minutes to read
UniQure NV
UniQure Directors Bet Big: Gut Robert Buys €14.08‑Shares Amid 25‑Euro Sales—Insider Confidence Amid Volatile Gene‑Therapy Stock
Insider trades at uniQure reveal a cautious bullish stance: director Robert buys deep‑value shares, sells near‑peak prices, signaling confidence in upcoming gene‑therapy breakthroughs and potential rally.
3 minutes to read
Kaye Jack’s Pre‑Scheduled Buy‑Sell Swap at uniQure NV Signals Insider Confidence Ahead of FDA Milestone.
Explore Kaye Jack’s pre‑planned uniQure NV buy‑sell trade, revealing insider confidence, premium sales, and potential upside amid FDA milestones.
3 minutes to read